Literature DB >> 330086

F1 hybrid antiparental cell-mediated lympholysis: a comparison with bone marrow graft rejection and with cell-mediated lympholysis to alloantigens.

G M Shearer, G Cudkowicz, A M Schmitt-Verhulst, T G Rehn, H Waksal, P D Evans.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 330086     DOI： 10.1101/sqb.1977.041.01.059

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN： 0091-7451


× No keyword cloud information.
  7 in total

1.  The genetic control of syngeneic delayed-type hypersensitivity (syn-DTH).

Authors:  N Tarcic; D Naor
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Genetic resistance of CBA and A mice to transplanted lymphoid and hemopoietic cells of CBA.M523 mutants and their F1 hybrids.

Authors:  L N Fontalin; T K Kondratjeva; T K Novikova; Z K Blandova
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

Review 3.  Lymphocyte-mediated lysis of tumor cells in vitro. Antigen-restricted clonal and unrestricted polyclonal effects.

Authors:  E Klein
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Pathology, immunology and virology of the host versus graft syndrome.

Authors:  R C Hard; S S Cross
Journal:  Surv Immunol Res       Date:  1983

5.  The role of humoral immunity and the contribution of the F1 anti-parental effect in the rejection of a Moloney leukemia virus-induced lymphoma graft.

Authors:  B Asjö; E Klein; E M Fenyö; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Activation or suppression of bactericidal activity of macrophages during a graft-versus-host reaction against I-A and I-J-region differences, respectively.

Authors:  R M Zinkernagel
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

7.  Hybrid resistance to EL-4 lymphoma cells. I. Characterization of natural killer cells that lyse EL-4 cells and their distinction from marrow-dependent natural killer cells.

Authors:  V Kumar; E Luevano; M Bennett
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.